Last updated on March 2020

Study to Evaluate the Safety Tolerability Pharmacokinetics and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate in Patients With Metastatic Castration Resistant Prostate Cancer

Brief description of study

The study medication (BAY 2315497 Injection) is a thorium-227 labeled immuno-conjugate, specific for the prostate-specific membrane antigen (PSMA), which will be evaluated in patients with metastatic castration resistant prostate cancer. In this study, this investigational medication will be administered to patients for the first time. The primary objective of the study is to define the safety and tolerability profile and Maximal Tolerated Dose (MTD) of BAY 2315497 Injection. The secondary objectives are to determine the recommended dose for further clinical development and to investigate how the study drug is distributed and cleared from the body.

Clinical Study Identifier: NCT03724747

Find a site near you

Start Over

HUS, Meilahden sairaala

Helsinki, Finland
  Connect »